Drug Delivery Systems for Metabolic Disorders

1st Edition - August 26, 2022
Editors: Harish Dureja, Narasimha Murthy, Peter Wich, Kamal Dua
Language: English
Paperback ISBN:
9 7 8 - 0 - 3 2 3 - 9 9 6 1 6 - 7
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 9 9 6 3 3 - 4

Drug Delivery Systems for Metabolic Disorders presents the most recent developments on the targeted delivery of drugs to deal with metabolic disorders in a safe, compliant… Read more

Purchase options

Institutional subscription on ScienceDirect

Request a sales quote

Drug Delivery Systems for Metabolic Disorders presents the most recent developments on the targeted delivery of drugs to deal with metabolic disorders in a safe, compliant and continuous way. The book covers recent developments in advanced drug delivery systems in various metabolic disorders, including disturbances in protein, lipid, carbohydrate and hormone metabolism and lysosomal and mitochondrial disorders. It provides a brief introduction to metabolic disorders, along with a focus on the current landscape and trends in understanding disease pathology using different in vitro and in vivo models required for clinical applications and developments of new therapeutics.

Each subsequent chapter covers drug delivery systems dedicated to metabolic diseases caused by disturbances in protein, lipid, carbohydrate and hormone metabolism. Then, it moves on to cover lysosomal storage disorders and applications of phytopharmaceuticals in this context. This is the perfect reference for researchers in pharmaceutical science who are interested in developing new treatments for metabolic diseases.

Cover image
Title page
Table of Contents
Copyright
List of contributors
About the editors
Chapter 1. Introduction to metabolic disorders
Abstract
1.1 Metabolic disorders due to deregulation of protein/amino acid metabolism
1.2 Metabolic disorders due to deregulation of lipid metabolism
1.3 Metabolic disorder due to deregulation in carbohydrate metabolism
1.4 Metabolic disorder due to disturbance in hormone metabolism
1.5 Metabolic disorder due to deregulation in lysosomal storage disorders
1.6 Metabolic disorder due to deregulation in mitochondrial disorders
References
Further reading
Chapter 2. Cellular and molecular mechanisms involved in metabolic disorders
Abstract
2.1 Introduction
2.2 Alterations in single-minded protein-1: downstream mediator of leptin-melanocortin pathway
2.3 Link between osteocalcin deficiency and insulin resistance
2.4 Aberrations in the JAK-STAT pathway
2.5 Alteration in AMPK activity: insulin resistance and cardiovascular problems
2.6 Conclusion
Acknowledgments
References
Chapter 3. Current practices in drug delivery for metabolic disorders
Abstract
3.1 Introduction
3.2 Oral drug delivery approaches
3.3 Site-specific drug delivery approaches
3.4 Targeted drug delivery
3.5 Intelligent drug delivery
3.6 Conclusion
Acknowledgments
References
Chapter 4. Recent developments in the treatment of amyloidosis
Abstract
4.1 Introduction
4.2 The history of amyloidosis
4.3 Amyloid fibril
4.4 Conclusion
Acknowledgments
References
Chapter 5. Advanced drug delivery systems targeting to improve therapeutic outcomes in porphyria
Abstract
5.1 Introduction
5.2 Prevalence
5.3 Pathophysiology
5.4 Symptoms and diagnosis
5.5 Treatment strategies
5.6 Overview of treatment drugs and current treatment problems
5.7 Novel therapies
5.8 Summary and conclusion
References
Chapter 6. Advanced drug delivery systems targeting kwashiorkor involving a disturbance in protein metabolism
Abstract
6.1 Introduction
6.2 Physiological changes associated with kwashiorkor disease
6.3 Biochemical manifestations and metabolic disorders associated with kwashiorkor disease
6.4 Signs, symptoms, and clinical manifestations in kwashiorkor
6.5 Current treatment of kwashiorkor
6.6 Metabolic disturbances associated with kwashiorkor
6.7 Role of nanotechnology in drug-delivery
6.8 Different types of drug delivery vehicles
6.9 Advanced drug delivery system targeting kwashiorkor
6.10 Conclusion
References
Chapter 7. Advanced drug delivery systems targeting metabolic disorders: erythropoietic protoporphyria
Abstract
7.1 Introduction
7.2 Etiology
7.3 Clinical features
7.4 Diagnosis
7.5 Pathophysiology
7.6 Genotype-phenotype correlations
7.7 Current and emerging therapies
7.8 Conclusion and future perspective
References
Chapter 8. Combating atherosclerosis with nanodrug delivery approaches: from bench side to commercialization
Abstract
8.1 Introduction
8.2 Atherosclerosis
8.3 Nanoformulations for the treatment of atherosclerosis with implementation of quality by design
8.4 Dendrimers
8.5 Challenges in translating nanodrug delivery systems from bench to bedside
8.6 Conclusion
References
Chapter 9. Advanced drug delivery systems in the management of Gaucher disease
Abstract
9.1 History
9.2 Epidemiology
9.3 Etiology
9.4 Pathogenesis
9.5 Clinical classification of Gaucher disease
9.6 Management of Gaucher disease
9.7 Conclusion
References
Chapter 10. Advanced drug delivery systems focusing the metabolic disorders due to deregulation of lipid metabolism: Niemann Pick Disease and Letterer-Siwe disease
Abstract
10.1 Introduction
10.2 Neimann’s Pick disease
10.3 Etiology
10.4 Stage 1: early lesion’s phase
10.5 Stage 2: fibrous phase
10.6 Stage 3: extra lesion phase
10.7 Diagnosis Letterer Siwe disease
10.8 Prospects
10.9 Conclusion
References
Chapter 11. Genetic disease and Niemann-Pick disorders: novel treatments and drug delivery systems
Abstract
11.1 Introduction to genetic disorders
11.2 Classification of inherited metabolic disorders
11.3 Physiology of lipid metabolism and diseases associated with lipid metabolism
11.4 Essential aspects of Niemann-Pick disease: prevalence, pathophysiology, diagnosis, and symptoms
11.5 Current therapeutic strategies to treat Niemann-Pick disease
11.6 Problems associated with the current therapeutic strategies to treat Niemann-Pick disease
11.7 Possible novel drug delivery systems to improve therapeutic efficacy in Niemann-Pick disease
References
Chapter 12. Novel 3D printing drug delivery system for the prevention and treatment of Atherosclerosis
Abstract
12.1 Importance of 3D printing drug delivery systems
12.2 Pathophysiology of atherosclerosis
12.3 Drugs used for the prevention and treatment of atherosclerosis
12.4 Problems with current oral drug delivery
12.5 Customized 3D printed dosage forms for atherosclerosis and associated diseases
12.6 Conclusion
References
Chapter 13. Advanced drug delivery systems to treat Huntington’s disease: challenges and opportunities
Abstract
13.1 Introduction
13.2 Global prevalence and economic burden
13.3 Pathophysiology
13.4 Pharmacological management of Huntington’s disease
13.5 Herbal therapy
13.6 Challenges associated with conventional therapy and the need for advanced drug delivery systems
13.7 Conclusion and perspectives
References
Chapter 14. Advanced drug delivery systems for targeting obesity
Abstract
14.1 Introduction
14.2 Reason for weight gain
14.3 Obesity management
14.4 Conventional anti-obesity treatments
14.5 Advanced drug delivery systems
14.6 Conclusion and future prospectus
References
Chapter 15. Advanced drug delivery systems for treatment of diabetes mellitus
Abstract
15.1 Introduction
15.2 Antidiabetic medication-related complications
15.3 Possibilities provided by the various Novel drug delivery systems
15.4 Development and designing of various advanced drug delivery systems for diabetes treatment
15.5 Prospects and conclusion
References
Chapter 16. Advanced drug delivery system in the treatment of hyperglycemia and hypoglycemia
Abstract
16.1 Introduction
16.2 Conventional treatment for glucose metabolism disorders
16.3 Alternative approaches to diabetes
16.4 Nanomaterials for treatment of diabetes
16.5 Advances in insulin delivery
16.6 Conclusion and future perspectives
References
Chapter 17. Emerging drug delivery in the treatment of hyperpituitarism and hypopituitarism
Abstract
17.1 Introduction
17.2 Treatment of hypopituitarism and hyperpituitarism
17.3 Conclusion and future perspective
References
Chapter 18. Advance drug delivery systems targeting hypoparathyroidism and hyperparathyroidism
Abstract
18.1 Introduction
18.2 Pathophysiology
18.3 Clinical manifestations
18.4 Current treatments for hypoparathyroidism and hyperparathyroidism
18.5 Conclusion
References
Chapter 19. An update on the development of advanced drug delivery systems for the treatment of hyperthyroidism
Abstract
19.1 Introduction
19.2 Epidemiology of hyperthyroidism
19.3 Common etiology and pathogenesis of hyperthyroidism
19.4 Diagnosis of hyperthyroidism
19.5 Advancement in drug delivery systems/techniques for the management of hyperthyroidism
19.6 Potential future therapies
19.7 Nanoparticles: promising auxiliary agents for therapy of hyperthyroidism and associated diseases
19.8 Conclusions and future perspectives
References
Chapter 20. Advanced drug delivery systems involving lysosomal storage disorders for Schinder disease and other disorders
Abstract
20.1 Introduction to lysosomal storage disorders
20.2 Potential targets for lysosomal disorders
20.3 Potential strategies using advanced delivery systems for lysosomal storage diseases
20.4 Attempts in treatment of lysosomal storage diseases by utilization of gene therapy
20.5 Current novel lysosomal storage disorder therapies in clinical trials
Acknowledgments
References
Chapter 21. Advanced drug delivery systems involving lysosomal storage disorders for Fabry disease
Abstract
21.1 Introduction
21.2 Classification and clinical manifestations
21.3 Diagnosis
21.4 Treatments
21.5 New approaches for the treatment of Fabry disease
21.6 Advanced drug delivery systems in Fabry disease
21.7 Conclusion
References
Chapter 22. Drug delivery systems in Krabbe disease—present and prospective approaches
Abstract
22.1 Introduction
22.2 Genetic background
22.3 Pathophysiology
22.4 Current approaches and challenges
22.5 Potential targets and approaches
22.6 Conclusion
References
Chapter 23. Strategies to combat Tay-Sachs disease
Abstract
23.1 Introduction
23.2 Overview of Tay-Sachs disease
23.3 Treatment strategies and management
23.4 Developmental treatment for Tay-Sachs disease
23.5 Conclusion
References
Chapter 24. Sandhoff disease: pathology and advanced treatment strategies
Abstract
24.1 Lysosomal storage disease
24.2 Sandhoff disease
24.3 Etiology and pathogenesis
24.4 Prevalence and occurrence
24.5 Clinical characteristics
24.6 Treatment
24.7 Carriers for lysosomal drug delivery
24.8 Liposomes
24.9 Future developments on sandhoff disease
24.10 Conclusion
References
Chapter 25. Nanomaterials-based drug delivery approaches for metabolic disorders
Abstract
25.1 Introduction
25.2 Routes of drug delivery for metabolic disorders
25.3 Nanomaterial-based drug delivery approaches
25.4 Applications of nano-based drug delivery systems to treat metabolic disorders
25.5 Limitations of using nano-based drug delivery approach
25.6 Future prospective
25.7 Conclusion
References
Chapter 26. Eye in metabolic disorders: manifestations and drug delivery systems
Abstract
26.1 Introduction
26.2 Diabetic retinopathy (Dr)
26.3 Glaucoma
26.4 Cataract
26.5 Conclusion
References
Chapter 27. Advanced drug delivery systems involving mitochondrial disorders
Abstract
27.1 Introduction
27.2 Mitochondrial DNA
27.3 Clinical manifestations of mitochondrial disorders
27.4 Mitochondrial diseases
27.5 Delivery systems for mitochondrial diseases
27.6 Peptide-based mitochondrial-targeted strategy
27.7 Mitochondrial targeting sequences
27.8 Szeto–Schiller peptides
27.9 Vehicle-based mitochondrial-targeted strategy
27.10 MITO-Porter
27.11 Mesoporous silica nanoparticles
27.12 Conclusions
References
Chapter 28. Applications of phytopharmaceuticals in targeting metabolic disorders
Abstract
28.1 Introduction
28.2 Role of polyphenols and terpenoids in the treatment of metabolic disorders
28.3 Management of metabolic disorders via phytomedicinal therapy
28.4 Future prospective of phytopharmaceuticals for metabolic disorders
28.5 Conclusion
References
Chapter 29. Phytonanoparticles toward the treatment of diabetes
Abstract
29.1 What is diabetes?
29.2 Classification and treatment available for diabetes
29.3 Treatment available for diabetes
29.4 Nanoparticles for the treatment of diabetes
29.5 Advantages of phytoderived nanoparticles
29.6 List of nanoparticles for the treatment of diabetes
29.7 List of phytonanoparticles for the treatment of diabetes
29.8 Conclusion
Acknowledgments
References
Chapter 30. Role of nutraceuticals in metabolic syndrome
Abstract
30.1 Introduction
30.2 Definition, pathogenesis, and pathophysiology of metabolic syndrome
30.3 Applications of nutraceuticals in the management of Ms
30.4 Conclusion
References
Chapter 31. Latest advances of phytomedicine in drug delivery systems for targeting metabolic disorders
Abstract
31.1 Introduction
31.2 Significance of phytomedicines as therapeutics
31.3 Pathophysiology of metabolic syndrome
31.4 Phytomedicines in drug delivery system
31.5 Future perspective
31.6 Conclusion
References
Chapter 32. Clinical trials, future prospects and challenges of drug delivery in combating metabolic disorders
Abstract
32.1 Challenges faced by advanced delivery systems
32.2 Future prospects
32.3 Conclusion
References
Index

Harish Dureja

Dr. Harish Dureja is Professor and Head, Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak. Dr. Dureja is also the Director, Centre for IPR Studies and Director, Professional Consultancy Cell. Dr. Dureja has more than 22 years of teaching experience. He also holds 18 years research experience in the field of nanoparticulate drug delivery, regulatory affairs and in silico ADME modeling. Dr. Dureja has been awarded with Gold-Medal for the best Ph.D. thesis and research projects worth 1.2 Crore from various funding agencies. He has filed an Indian patent and written a book and authored more than twenty five book chapters. He has published 265 publications in various international and national journals of repute. He worked as Chairman-Scientific Services Committee (LOC) during 69th IPC at Chitkara University, Raj-pura. He also worked as content writer for e-Pathashala program of Ministry of Human Resources Development for Post Graduate course of Pharmaceutical Sciences for the paper novel drug delivery system. He has delivered more than 180 invited Lectures in various conferences, seminars and symposiums and has guided 60 PG scholars and 10 students for doctoral work. He has been awarded the Gold-Medal for Best Ph.D. Thesis, Best Paper Award - Prof. M.L. Khorana Memorial Prize Award – 2005 and Dr. R.L. Nicore award - 2018. He has published six special issues as a Guest Editor for the Journals published by Bentham Science Publishers, and one issue published by Frontiers, Switzerland. He is currently also serving as President, Association of Pharmaceutical Teachers of India (APTI), Haryana State Branch.

Affiliations and expertise

Professor, Department of Pharmaceutical Sciences, Maharshi Dayanand University, India

Narasimha Murthy

Dr. S. Narasimha Murthy is the CSO of Topical Products Testing LLC, USA. He was former Professor of Pharmaceutics and Drug Delivery at the University of Mississippi School of Pharmacy, USA for over 15 years. Dr. Murthy is a pioneer in nanotechnology-based delivery systems, microneedles and microstructured delivery technologies of drug delivery and diagnosis, dermal and transdermal delivery of drugs and nose to brain delivery of therapeutics. His research programs are funded by NIH, FDA, and Pharmaceutical companies. He has published over 130 research papers and presented over 250 scientific posters in various national and international scientific meetings. He has authored two books and over fifteen book chapters. He is serving on the Editorial Board of several journals including AAPS Pharm Sci Tech, DDIP and J Pharm. Sci. He is a consultant to pharmaceutical and medical device companies in the USA, Israel, Italy, and India. Dr. Murthy has received several awards such as the New Investigator award and Cumberl and Researcher of the year from the University of Mississippi, Global Indus Technovator award from MIT, Endowed Chair for Research at the Ohio Northern University and he was inducted as the Fellow of the American Association of Pharmaceutical Scientists in 2017 and was bestowed with Distinguished Scientist award by American Association of Indian Pharmaceutical Scientists. Dr. Murthy is also a scientific philanthropist. He is the Founder Director of a non-profit research organization, Institute for Drug Delivery and Biomedical Research in Bangalore, India (www.IDBresearch.com).

Affiliations and expertise

Professor of Pharmaceutics and Drug Delivery, University of Mississippi, USA

Peter Wich

Dr. Peter Wich leads the Research Lab for Functional Biopolymers at the University of New South Wales in Sydney (Australia). His primary research interests are in the fields of macromolecular chemistry at the interface between nanotechnology and bioorganic chemistry. His lab focuses on the chemical modification of natural biopolymers with the aim to engineer new multi-functional and biocompatible materials for applications in drug delivery, nanomedicine, bio-catalysis, and 3D printing. Dr. Wich is an expert in the field of biopolymer modification and the (self) assembly of these new biohybrid materials into nanoparticles for dynamic drug delivery systems. Dr. Wich has been awarded more than 20 prizes and scholarships for his research, including the Innovation Prize in Medicinal/Pharmaceutical Chemistry for his work on bioinspired nanomaterials (jointly awarded by the Awarded by the German Chemical and the German Pharmaceutical Society) and the Galenus Technology Prize, for his innovative achievements in the field of Pharmaceutical Technology. In 2016, he was selected as “Young Member” of the Academy of Sciences and Literature in Mainz, Germany. In recognition of his achievements, he was selected in 2019 to represent the element Roentgenium in the IUPAC Periodic Table of Younger Chemists. In 2019 Peter was named Emerging Investigator of the Journal “Soft Matter” and in 2020 he was selected as Polymer Chemistry Emerging Investigator.

Affiliations and expertise

Senior Lecturer and Junior Professor for Bioorganic & Macromolecular Chemistry, School of Chemical Engineering, University of New South Wales,

Kamal Dua

Dr. Kamal Dua is a Senior Lecturer in the Discipline of Pharmacy at the Graduate School of Health, University of Technology Sydney (UTS), Australia. He has research experience of over many years in the field of drug delivery systems targeting inflammatory diseases. Dr. Dua researches in two complementary areas; drug delivery and immunology, specifically addressing how these disciplines can advance one another, helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr. Dua’s research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as Interleukins and microRNAs and developing new and effective drug delivery formulations for the management of chronic airway diseases. He has published more than 80 research articles in peer-reviewed international journals and authored or co-authored four books. He is an active member of many national and international professional societies.

Affiliations and expertise

Senior Lecturer, Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health

Drug Delivery Systems for Metabolic Disorders

Purchase options

Institutional subscription on ScienceDirect

Harish Dureja

Narasimha Murthy

Peter Wich

Kamal Dua